NYSE · XXII
Consumer Defensive · Tobacco
$4.33
Up+$0.22 (+5.23%)
Updated Aug 15, 2026, 3:27 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
XXII closed at $4.33 after 21 trading sessions, down 0.12% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $3.99 | $4.35 | $3.99 | $4.325 | 9.55K |
| Aug 13, 2026 | $4.33 | $4.33 | $3.73 | $4.11 | 30.49K |
| Aug 12, 2026 | $4.37 | $4.565 | $4.31 | $4.31 | 11.9K |
| Aug 11, 2026 | $4.2365 | $4.54 | $4.2001 | $4.40 | 4.18K |
| Aug 10, 2026 | $4.29 | $4.50 | $4.23 | $4.35 | 5.61K |
| Aug 7, 2026 | $4.29 | $4.5315 | $4.10 | $4.29 | 9.86K |
| Aug 6, 2026 | $4.29 | $4.33 | $4.29 | $4.32 | 1.95K |
| Aug 5, 2026 | $4.40 | $4.49 | $4.04 | $4.36 | 8.42K |
| Aug 4, 2026 | $4.27 | $4.4399 | $4.185 | $4.41 | 15.93K |
| Aug 3, 2026 | $4.06 | $4.22 | $4.04 | $4.20 | 5.12K |
| Jul 31, 2026 | $4.05 | $4.05 | $3.90 | $4.00 | 8.6K |
| Jul 30, 2026 | $3.79 | $3.87 | $3.61 | $3.87 | 7.04K |
| Jul 29, 2026 | $3.87 | $3.96 | $3.72 | $3.72 | 10.34K |
| Jul 28, 2026 | $4.07 | $4.07 | $3.90 | $3.93 | 4.86K |
| Jul 27, 2026 | $4.11 | $4.14 | $3.91 | $4.14 | 14.18K |
| Jul 24, 2026 | $4.65 | $4.65 | $4.17 | $4.27 | 8.18K |
| Jul 23, 2026 | $4.115 | $4.6799 | $4.115 | $4.65 | 8.74K |
| Jul 22, 2026 | $4.30 | $4.39 | $4.16 | $4.265 | 27.69K |
| Jul 21, 2026 | $4.15 | $4.5099 | $4.15 | $4.5099 | 6.88K |
| Jul 20, 2026 | $4.24 | $4.32 | $4.2101 | $4.3199 | 4.45K |
| Jul 17, 2026 | $4.1353 | $4.5999 | $4.1353 | $4.33 | 17.16K |
The latest Smart Investors Daily articles mentioning XXII.
XXII research
Company profile and research snapshot.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 23, 2023 | Roth MKM | Buy | — |
| Aug 17, 2023 | Alliance Global Partners | Neutral | — |
| Aug 15, 2023 | Dawson James | Buy | — |
| Aug 15, 2023 | TD Cowen | Market Perform | — |
| Nov 9, 2022 | Alliance Global Partners | Buy | — |
No generated briefing is available yet.
Yahoo · Aug 13, 2026
Company expands Pinnacle VLN distribution to nearly 150 stores in Metro New York while navigating transition away from low-margin contract manufacturing.
Benzinga · Aug 13, 2026
22nd Century Group (NASDAQ:XXII) reported quarterly losses of $(15.60) per share which missed the analyst consensus estimate of $(6.00) by 160 percent. This is a 100.48 percent decrease over earnings of $3.28 thousand
SeekingAlpha · Aug 13, 2026
22nd Century Group, Inc. (XXII) Q2 2026 Earnings Call August 13, 2026 8:00 AM EDTCompany ParticipantsDaniel Otto - CFO & Principal Accounting...
Yahoo · Aug 13, 2026
Advances VLN® Commercialization Through Expanded Retail Support and Brand-Building Initiatives MOCKSVILLE, N.C., Aug. 13, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the leader in low-nicotine tobacco, low-nicotine cigarettes and only tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced results for the second quarter ended June 30, 2026, and provided an update on recent commercial, regulatory and operational activitie
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning XXII.
